The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Apamin administration impact on miR-219 and miR-155-3p expression in cuprizone induced multiple sclerosis model
Abstract
Multiple sclerosis (MS) is a chronic debilitating disease that attacks the central nervous system. This study aims to investigate miR-219 and miR-155-3p expression levels involved in the myelination process following the administration of apamin peptide in the model of multiple sclerosis disease. Forty-four 8 week C57BL/6 male mice (22 ± 5 g) randomly divided into six groups. Apamin (100 µg/kg/BW) was administered intraperitoneally as a co-treatment during phase I (demyelination) or post-treatment phase II (remyelination) twice a week in cuprizone induced MS model. At the end of study myelin content and microRNA expression levels were measured with LFB staining and quantitative Real-Time PCR method, respectively. It was observed that the intended microRNAs were dysregulated during the different phases of disease induction. After 6 weeks of cuprizone exposure, miR-219 downregulated in phase I in comparison with the negative control. On the other hand, the apamin co-treatment significantly inhibit the miR-155-3p upregulation during the phase I as compared with the cuprizone group (p < 0.0001). Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque formation during the exacerbation phase of the MS disease. Apamin has more impact on the miR155-3p reduction in phase I than miR-219 elevation in phase II. It could be considered as a therapeutic option for decreasing plaque…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apamin can reduce miR-155-3p expression and then reduce plaque formation and demyelination during MS disease (Gholami et al. 2020).”
From MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis (2025) · cites this paper as Gholami et al. 2020
Citations
Cites
Dynamics of oligodendrocyte generation in multiple sclerosis
Yeung, M. S. Y., Djelloul, M., Steiner, E., Bernard, S., Salehpour, M., Possnert, G., Brundin, L., & Frisén, J. (2019) · Nature · doi:10.1038/s41586-018-0842-3 · Cited by 376
Cardoso, A. L., Guedes, J. R., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03514.x · Cited by 336
miR‐155 as a multiple sclerosis–relevant regulator of myeloid cell polarization
Moore, C. S., Rao, V. T. S., Durafourt, B. A., Bedell, B. J., Ludwin, S. K., Bar‐Or, A., & Antel, J. P. (2013) · Annals of Neurology · doi:10.1002/ana.23967 · Cited by 219 · cited 2×
“On the other hand, it was observed that miR-155 was increased in white brain tissue compared to the collected lesions from several patients with relapsing–remitting, primary progressive, and secondary progressive [21].”
Background
Flagged first, then by citations
Research works printed but not linked: 34
- Höftberger R, Lassmann H (2018) Inflammatory demyelinating diseases of the central nervous system. In: Handbook of clinical neurology, vol 145. Elsevier, pp 263–283 · DOI
- Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191 · DOI
- Aliomrani M, Sahraian MA, Shirkhanloo H, Sharifzadeh M, Khoshayand MR, Ghahremani MH (2016) Blood concentrations of cadmium and lead in multiple sclerosis patients from Iran. Iran J Pharm Res 15(4):825
- Aliomrani M, Sahraian MA, Shirkhanloo H, Sharifzadeh M, Khoshayand MR, Ghahremani MH (2017) Correlation between heavy metal exposure and GSTM1 polymorphism in Iranian multiple sclerosis patients. Neurol Sci 38(7):1271–1278 · DOI
- Fratellone PM, Tsimis F, Fratellone G (2016) Apitherapy products for medicinal use. J Altern Complement Med 22(12):1020–1022 · DOI
- Li C, Pazgier M, Liu M, Lu W, Lu W (2009) Apamin as a template for structure-based rational design of potent peptide activators of p53. Angew Chem 121(46):8868–8871 · DOI
- Park J, Jang KM, Park K-K (2020) Apamin suppresses LPS-induced neuroinflammatory responses by regulating SK CHANNELS and TLR4-mediated signaling pathways. Int J Mol Sci 21(12):4319 · DOI
- Hugues M, Romey G, Duval D, Vincent J-P, Lazdunski M (1982) Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor. Proc Natl Acad Sci 79(4):1308–1312 · DOI
- Kim S-J et al (2012) The protective effect of apamin on LPS/fat-induced atherosclerotic mice. Evid-Based Complement Altern Med · DOI
- Zhao Y et al (2015) Toxins targeting the Kv1. 3 channel: potential immunomodulators for autoimmune diseases. Toxins 7(5):1749–1764 · DOI
- Valle Reyes JS, Valencia Cruz G, Liñan Rico L, Pottosin I, Dobrovinskaya O (2018) Differential activity of voltage-and Ca2+-dependent potassium channels in leukemic T cell lines: Jurkat cells represent an exceptional case. Front Physiol 9:499 · DOI
- Thei L, Imm J, Kaisis E, Dallas ML, Kerrigan TL (2018) Microglia in alzheimer’s disease: a role for ion channels. Front Neurosci 12(676):10–3389
- Bozic I et al (2019) The potassium channel Kv1. 5 expression alters during experimental autoimmune encephalomyelitis. Neurochem Res 44(12):2733–2745 · DOI
- Maldonado PP, Vélez-Fort M, Levavasseur F, Angulo MC (2013) Oligodendrocyte precursor cells are accurate sensors of local K+ in mature gray matter. J Neurosci 33(6):2432–2442 · DOI
- de Planell-Saguer M, Rodicio MC (2011) Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 699(2):134–152 · DOI
- Dugas JC et al (2010) Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron 65(5):597–611 · DOI · Paper page
- Zhao X et al (2010) MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 65(5):612–626 · DOI · Paper page
- Mazloumfard F, Mirian M, Eftekhari S-M, Aliomrani M (2020) Hydroxychloroquine effects on miR-155–3p and miR-219 expression changes in animal model of multiple sclerosis. Metab Brain Dis 1–9 · DOI · Paper page
- Dong HW (2008) The Allen reference atlas: a digital color brain atlas of the C57Bl/6J male mouse. Wiley, New York
- Junker A, Hohlfeld R, Meinl E (2011) The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 7(1):56 · DOI · Paper page
- Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L (2012) Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 39(5):6219–6225 · DOI
- Zhang J et al (2017) MiR-146a promotes remyelination in a cuprizone model of demyelinating injury. Neuroscience 348:252–263 · DOI · Paper page
- Mohammadi-Rad M, Ghasemi N, Aliomrani M (2019) Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis. Res Pharm Sci 14(5):424. https://doi.org/10.4103/1735-5362.268203 · DOI
- Dugas JC, Notterpek L (2011) MicroRNAs in oligodendrocyte and Schwann cell differentiation. Dev Neurosci 33(1):14–20 · DOI
- McCoy CE (2017) miR-155 dysregulation and therapeutic intervention in multiple sclerosis. In: Regulation of inflammatory signaling in health and disease. Springer,, pp 111–131. · DOI · Paper page
- Dutta R et al (2013) Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol 73(5):637–645 · DOI · Paper page
- Chen C, Zhou Y, Wang J, Yan Y, Peng L, Qiu W (2018) Dysregulated microRNA involvement in multiple sclerosis by induction of T helper 17 cell differentiation. Front Immunol 9:1256 · DOI
- Liu S et al (2017) miR-219 attenuates demyelination in cuprizone-induced demyelinated mice by regulating monocarboxylate transporter 1. Eur J Neurosci 45(2):249–259 · DOI
- Yavarpour-Bali H, Nakhaei-Nejad M, Yazdi A, Ghasemi-Kasman M (2020) Direct conversion of somatic cells towards oligodendroglial lineage cells: a novel strategy for enhancement of myelin repair. J Cell Physiol 235(3):2023–2036 · DOI
- Huang H, Zhao X-F, Zheng K, Qiu M (2013) Regulation of the timing of oligodendrocyte differentiation: mechanisms and perspectives. Neurosci Bull 29(2):155–164 · DOI
- Lescher J et al (2012) MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions. J Neuroimmunol 246(1–2):27–33 · DOI
- Henry RJ et al (2019) Inhibition of miR-155 limits neuroinflammation and improves functional recovery after experimental traumatic brain injury in mice. Neurotherapeutics 16(1):216–230 · DOI
- Mycko MP, Cichalewska M, Cwiklinska H, Selmaj KW (2015) miR-155-3p drives the development of autoimmune demyelination by regulation of heat shock protein 40. J Neurosci 35(50):16504–16515 · DOI · Paper page
- Ceppi M et al (2009) MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci 106(8):2735–2740 · DOI · Paper page
Cited by
Sorted by citations
MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis
Asl, E. R., Hosseini, S. E., Tahmasebi, F., Bolandi, N., & Barati, S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01578-6 · Cited by 19
Metadata
- Authors
- Gholami, S., Mirian, M., Eftekhari, S. M., & Aliomrani, M.
- Venue
- Molecular Biology Reports
- Published
- 2020-11
- Volume
- 47
- Issue
- 11
- Pages
- 9013-9019
- ISSN
- 0301-4851
- 1573-4978
- Cited by
- 16
- References
- 3
- Language
- en
- Funders
- Isfahan University of Medical Sciences (297134)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review